Triple inhaled therapy in stable chronic obstructive pulmonary disease

The earlier, the better?

Sabina Antonela Antoniu, Mauro Carone, Italo Sampablo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.

Original languageEnglish
Pages (from-to)1039-1042
Number of pages4
JournalExpert Opinion on Pharmacotherapy
Volume11
Issue number6
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Muscarinic Antagonists
Bronchodilator Agents
Therapeutics
Budesonide
Health Status
Morbidity
Lung
Tiotropium Bromide

Keywords

  • Budesonide/formoterol combination
  • COPD
  • Tiotropium
  • Triple therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Triple inhaled therapy in stable chronic obstructive pulmonary disease : The earlier, the better? / Antoniu, Sabina Antonela; Carone, Mauro; Sampablo, Italo.

In: Expert Opinion on Pharmacotherapy, Vol. 11, No. 6, 04.2010, p. 1039-1042.

Research output: Contribution to journalArticle

@article{9a55650797014993b8a4a15a34dbe923,
title = "Triple inhaled therapy in stable chronic obstructive pulmonary disease: The earlier, the better?",
abstract = "Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.",
keywords = "Budesonide/formoterol combination, COPD, Tiotropium, Triple therapy",
author = "Antoniu, {Sabina Antonela} and Mauro Carone and Italo Sampablo",
year = "2010",
month = "4",
doi = "10.1517/14656561003652450",
language = "English",
volume = "11",
pages = "1039--1042",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Triple inhaled therapy in stable chronic obstructive pulmonary disease

T2 - The earlier, the better?

AU - Antoniu, Sabina Antonela

AU - Carone, Mauro

AU - Sampablo, Italo

PY - 2010/4

Y1 - 2010/4

N2 - Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.

AB - Inhaled long-acting bronchodilators (of β2-agonist or muscarinic antagonist type) or corticosteroids are used in stable chronic obstructive pulmonary disease (COPD) treatment in a step-up approach according to disease severity. Consequently, in more severe disease triple therapy with two bronchodilators and an inhaled corticosteroid can often be encountered in clinical practice, but its short-and long-term effects on disease outcomes are not very well known. The results of a study evaluating the short-term effects of budesonide/formoterol (inhaled corticosteroid/inhaled long-acting β2-agonist combination) and tiotropium (inhaled long-acting muscarinic antagonist) against tiotropium alone are analysed and discussed. On a short-term basis, triple therapy improves lung function, health status and disease morbidity irrespective of disease severity. Long-term benefits of triple inhaled therapy including the effects of its precocious use in less severe COPD subjects should be evaluated.

KW - Budesonide/formoterol combination

KW - COPD

KW - Tiotropium

KW - Triple therapy

UR - http://www.scopus.com/inward/record.url?scp=77949891785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949891785&partnerID=8YFLogxK

U2 - 10.1517/14656561003652450

DO - 10.1517/14656561003652450

M3 - Article

VL - 11

SP - 1039

EP - 1042

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -